{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:30:01Z","timestamp":1785767401599,"version":"3.56.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.clinbiochem.2019.09.001","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T19:10:58Z","timestamp":1567624258000},"page":"12-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography"],"prefix":"10.1016","volume":"74","author":[{"given":"Yunes","family":"Panahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen Sadeghi","family":"Ghahrodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Jamshir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Safarpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Bianconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pirro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Moshkani","family":"Farahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","article-title":"Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015","volume":"70","author":"Roth","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0010","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0015","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1002\/jcp.25767","article-title":"PCSK9 at the crossroad of cholesterol metabolism and immune function during infections","volume":"232","author":"Paciullo","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0020","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1111\/jcmm.13273","article-title":"Hepatitis C virus and proprotein convertase subtilisin\/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism","volume":"21","author":"Pirro","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0025","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacl.2018.05.012","article-title":"PCSK9 and neurocognitive function: should it be still an issue after FOURIER and EBBINGHAUS results?","volume":"12","author":"Mannarino","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0035","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCGENETICS.115.001129","article-title":"Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with Alirocumab, a PCSK9 monoclonal antibody","volume":"8","author":"Hopkins","year":"2015","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0040","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/CIRCULATIONAHA.115.018531","article-title":"Circulating Proprotein Convertase Subtilisin\/Kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors","volume":"133","author":"Leander","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0045","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/ATVBAHA.115.306172","article-title":"Association of Proprotein Convertase Subtilisin\/Kexin type 9 (PCSK9) with cardiovascular risk in primary prevention","volume":"35","author":"Zhu","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0050","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/eurheartj\/ehv568","article-title":"Plasma proprotein convertase subtilisin\/kexin type 9 levels and the risk of first cardiovascular events","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.atherosclerosis.2016.07.922","article-title":"Prediction of cardiovascular events with levels of proprotein convertase subtilisin\/kexin type 9: a systematic review and meta-analysis","volume":"252","author":"Vlachopoulos","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0060","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.vph.2014.03.004","article-title":"Risk prediction with proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment","volume":"62","author":"Werner","year":"2014","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0065","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacbts.2016.06.007","article-title":"Circulating PCSK9 and risk of myocardial infarction: the HUNT Study in Norway","volume":"1","author":"Laugsand","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0070","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2017.07.743","article-title":"Relationship of PCSK9 and urinary thromboxane excretion to cardiovascular events in patients with atrial fibrillation","volume":"70","author":"Pastori","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0075","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002426","article-title":"Proprotein convertase subtilisin\/Kexin type 9, C-reactive protein, coronary severity, and outcomes in patients with stable coronary artery disease: a prospective observational cohort study","volume":"94","author":"Li","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0080","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5551\/jat.RV17003","article-title":"PCSK9 and atherosclerosis - lipids and beyond","volume":"24","author":"Shapiro","year":"2017","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0085","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.hlc.2015.10.017","article-title":"Plasma Proprotein Convertase Subtilisin Kexin type 9 as a predictor of carotid atherosclerosis in asymptomatic adults","volume":"25","author":"Chan","year":"2016","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0090","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/ATVBAHA.115.306172","article-title":"Association of Proprotein Convertase Subtilisin\/Kexin type 9 (PCSK9) with cardiovascular risk in primary prevention","volume":"35","author":"Zhu","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0095","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.atherosclerosis.2016.08.038","article-title":"PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia","volume":"254","author":"Alonso","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0100","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/0004563217695351","article-title":"Association between plasma proprotein convertase subtisilin\/kexin type 9 concentration and coronary artery calcification","volume":"55","author":"Zhao","year":"2018","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","article-title":"PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study","volume":"248","author":"Cheng","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4093\/dmj.2017.0081","article-title":"Serum levels of PCSK9 are associated with coronary angiographic severity in patients with acute coronary syndrome","volume":"42","author":"Bae","year":"2018","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0115","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/07853890.2015.1042908","article-title":"Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease","volume":"47","author":"Li","year":"2015","journal-title":"Ann. Med."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00380-018-1218-1","article-title":"Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese","volume":"34","author":"Nose","year":"2019","journal-title":"Heart Vessel."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-511X-7-22","article-title":"Plasma PCSK9 levels are significantly modified by statins and fibrates in humans","volume":"7","author":"Mayne","year":"2008","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106294","article-title":"Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies","volume":"9","author":"Almontashiri","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0135","article-title":"Association between circulating proprotein convertase subtilisin\/kexin type 9 levels and prognosis in patients with severe chronic kidney disease","author":"Rasmussen","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0140","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/eurheartj\/ehv637","article-title":"Prognostic value of PCSK9 levels in patients with acute coronary syndromes","volume":"37","author":"Gencer","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0145","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tcm.2018.09.017","article-title":"Atherosclerosis and immunity: a perspective","volume":"29","author":"Abdolmaleki","year":"2018","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0150","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/01.HYP.0000255790.98391.9b","article-title":"Age-specific relationship of aortic pulse wave velocity with left ventricular geometry and function in hypertension","volume":"49","author":"Schillaci","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0155","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jacc.2013.05.016","article-title":"High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?","volume":"62","author":"Yousuf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0160","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/01.hjr.0000152243.51327.2a","article-title":"Attenuation of inflammation with short-term dietary intervention is associated with a reduction of arterial stiffness in subjects with hypercholesterolaemia","volume":"11","author":"Pirro","year":"2004","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0165","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2796.2011.02510.x","article-title":"Imbalance between endothelial injury and repair in patients with polymyalgia rheumatica: improvement with corticosteroid treatment","volume":"272","author":"Pirro","year":"2012","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease","volume":"352","author":"Nissen","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8010118","article-title":"Effect of statin therapy on arterial wall inflammation based on 18F-FDG PET\/CT: a systematic review and meta-analysis of interventional studies","volume":"8","author":"Pirro","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0180","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/dmrr.2712","article-title":"Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes","volume":"32","author":"Yang","year":"2016","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"4","key":"10.1016\/j.clinbiochem.2019.09.001_bb0190","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3945\/jn.116.235069","article-title":"Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors","volume":"147","author":"Krysa","year":"2017","journal-title":"J. Nutr."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0195","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41514-018-0026-2","article-title":"The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy","volume":"4","author":"Ikegami","year":"2018","journal-title":"NPJ Aging Mech. Dis."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0200","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/labinvest.2017.47","article-title":"Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation","volume":"97","author":"Kumar","year":"2017","journal-title":"Lab. Investig."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0205","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2174\/1389450120666190214141626","article-title":"Structure and function of proprotein convertase subtilisin\/kexin type 9 (PCSK9) in atherosclerosis","volume":"20","author":"Zhang","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2016.06.011","article-title":"A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification","volume":"251","author":"Goettsch","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0215","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1074248418775377","article-title":"Inhibition of aortic calcification by policosanol in dyslipidemic rabbits is enhanced by pentoxifylline: potential role of PCSK9","volume":"23","author":"Elseweidy","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0220","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.atherosclerosis.2011.08.035","article-title":"The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography","volume":"219","author":"Awan","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0225","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1002\/jcb.23221","article-title":"The role of Lrp5\/6 in cardiac valve disease: experimental hypercholesterolemia in the ApoE-\/- \/Lrp5-\/- mice","volume":"112","author":"Rajamannan","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0230","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.yexcr.2016.06.007","article-title":"WNT\/\u03b2-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression","volume":"345","author":"Cai","year":"2016","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0235","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.jacc.2018.06.078","article-title":"Effect of evolocumab on coronary plaque composition","volume":"72","author":"Nicholls","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0240","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.diabet.2017.07.009","article-title":"Circulating PCSK9 levels in acute coronary syndrome: results from the PC-SCA-9 prospective study","volume":"43","author":"Cariou","year":"2017","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.clinbiochem.2019.09.001_bb0245","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00395-017-0619-0","article-title":"Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease","volume":"112","author":"Glerup","year":"2017","journal-title":"Basic Res. Cardiol."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912019302553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912019302553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:54:17Z","timestamp":1757865257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912019302553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":49,"alternative-id":["S0009912019302553"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.09.001","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}